Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial

被引:26
作者
Brade, Anthony M. [1 ]
Wenz, Frederik [2 ]
Koppe, Friederike [3 ]
Lievens, Yolande [4 ]
San Antonio, Belen [5 ]
Iscoe, Neill A. [6 ,7 ]
Hossain, Anwar [8 ]
Chouaki, Nadia [9 ]
Senan, Suresh [10 ]
机构
[1] Trillium Hlth Partners, Div Radiat Oncol, 2200 Eglinton Ave W, Mississauga, ON L5M 2N1, Canada
[2] Univ Hosp Mannheim, Dept Radiat Oncol, Mannheim, Germany
[3] Inst Verbeeten, Dept Radiat Oncol, Tilburg, Netherlands
[4] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium
[5] Lilly Espana, Madrid, Spain
[6] Eli Lilly Canada, Toronto, ON, Canada
[7] Univ Toronto, Dept Radiat Oncol, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Neuilly Sur Seine, France
[10] Vrije Univ Amsterdam Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 101卷 / 04期
关键词
PEMETREXED PLUS CISPLATIN; RADIOTHERAPY; CONSOLIDATION; RECOMMENDATIONS; CARBOPLATIN;
D O I
10.1016/j.ijrobp.2018.04.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Chemoradiation therapy trials of different tumors, including lung cancer, have shown a correlation between protocol deviations and adverse outcomes. Radiation therapy quality assurance (RTQA) was mandated for all patients treated in the PROCLAIM trial evaluating 2 different chemoradiation therapy regimens. The RTQA results were evaluated from the PROCLAIM study, and the impact of irradiation deviations on efficacy outcomes was investigated. Methods and Materials: The study was conducted from 2008 to 2014. Review of the irradiation plan was mandated for all patients. Real-time review was performed prior to irradiation start for the first enrolled patient at each site and randomly in 20% of additional patients, with non-real-time review in the remainder. The RTQA criteria evaluated included planning target volume coverage, dose homogeneity, volume of lung receiving >= 20 Gy, and maximum point dose to spinal cord. Results: Major RTQA violations occurred in 40 of 554 patients, treated at 28 sites. Seven sites treated >= 2 patients with major violations. Stage IIIB disease and larger planning target volume were observed more frequently in patients with major violations. Major violations were more prevalent in sites treating either <6 patients or >15 patients. Patients treated at sites enrolling >= 2 patients with major violations (n = 86) had lower median overall survival (21.1 months vs 29.8 months; hazard ratio, 1.442) and progression-free survival (7.3 months vs 11.3 months; hazard ratio, 1.345) than patients treated at sites without major violations. These findings remained significant for overall survival on multivariate analysis. Conclusions: Major violations in treatment plans were uncommon in the PRO-CLAIM study, possibly reflecting mandatory RTQA. The RTQA violations were more frequent in patients requiring more complex chemoradiation therapy plans. Poorer observed outcomes at centers with multiple major violations are hypothesis generating. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:927 / 934
页数:8
相关论文
共 19 条
[1]  
[Anonymous], 2017, NCCN GUID NONSM CELL
[2]   Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline [J].
Bezjak, Andrea ;
Temin, Sarah ;
Franklin, Gregg ;
Giaccone, Giuseppe ;
Govindan, Ramaswamy ;
Johnson, Melissa L. ;
Rimner, Andreas ;
Schneider, Bryan J. ;
Strawn, John ;
Azzoli, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2100-U162
[3]   PHASE I TRIAL OF RADIATION WITH CONCURRENT AND CONSOLIDATION PEMETREXED AND CISPLATIN IN PATIENTS WITH UNRESECTABLE STAGE IIIA/B NON-SMALL-CELL LUNG CANCER [J].
Brade, Anthony ;
Bezjak, Andrea ;
MacRae, Robert ;
Laurie, Scott ;
Sun, Alex ;
Cho, John ;
Leighl, Natasha ;
Pearson, Shannon ;
Southwood, Bernadette ;
Wang, Lisa ;
McGill, Shauna ;
Iscoe, Neill ;
Shepherd, Frances A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (05) :1395-1401
[4]   Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].
Bradley, Jeffrey D. ;
Paulus, Rebecca ;
Komaki, Ritsuko ;
Masters, Gregory ;
Blumenschein, George ;
Schild, Steven ;
Bogart, Jeffrey ;
Hu, Chen ;
Forster, Kenneth ;
Magliocco, Anthony ;
Kavadi, Vivek ;
Garces, Yolanda I. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Cliff ;
Wynn, Raymond B. ;
Koprowski, Christopher ;
Meng, Joanne ;
Beitler, Jonathan ;
Gaur, Rakesh ;
Curran, Walter, Jr. ;
Choy, Hak .
LANCET ONCOLOGY, 2015, 16 (02) :187-199
[5]   Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer [J].
Cardenal, Felipe ;
Arnaiz, Maria Dolores ;
Moran, Teresa ;
Jove, Josep ;
Nadal, Ernest ;
Porta, Ruth ;
Sole, Josep Maria ;
Brao, Isabel ;
Palmero, Ramon ;
Fuentes, Rafael ;
Nunez, Inmaculada ;
Caveda, Elena ;
Cassinello, Alejo .
LUNG CANCER, 2011, 74 (01) :69-74
[6]   Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer [J].
Choy, Hak ;
Schwartzberg, Lee S. ;
Dakhil, Shaker R. ;
Garon, Edward B. ;
Gerber, David E. ;
Choksi, Janak K. ;
Govindan, Ramaswamy ;
Peng, Guangbin ;
Koustenis, Andrew ;
Treat, Joseph ;
Obasaju, Coleman .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (10) :1308-1316
[7]   Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial [J].
Chun, Stephen G. ;
Hu, Chen ;
Choy, Hak ;
Komaki, Ritsuko U. ;
Timmerman, Robert D. ;
Schild, Steven E. ;
Bogart, Jeffrey A. ;
Dobelbower, Michael C. ;
Bosch, Walter ;
Galvin, James M. ;
Kavadi, Vivek S. ;
Narayan, Samir ;
Iyengar, Puneeth ;
Robinson, Clifford G. ;
Wynn, Raymond B. ;
Raben, Adam ;
Augspurger, Mark E. ;
MacRae, RobertM. ;
Paulus, Rebecca ;
Bradley, Jeffrey D. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :56-+
[8]   European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer [J].
De Ruysscher, Dirk ;
Faivre-Finn, Corinne ;
Nestle, Ursula ;
Hurkmans, Coen W. ;
Le Pechoux, Cecile ;
Price, Allan ;
Senan, Suresh .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) :5301-5310
[9]   2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer [J].
Eberhardt, W. E. E. ;
De Ruysscher, D. ;
Weder, W. ;
Le Pechoux, C. ;
De Leyn, P. ;
Hoffmann, H. ;
Westeel, V. ;
Stahel, R. ;
Felip, E. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1573-1588
[10]   Does Quality of Radiation Therapy Predict Outcomes of Multicenter Cooperative Group Trials? A Literature Review [J].
Fairchild, Alysa ;
Straube, William ;
Laurie, Fran ;
Followill, David .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02) :246-260